Oriahnn 28 Day Kit
- RxCUI
- 2371768
- RxNorm name
- Oriahnn 28 Day Kit
- Display name
- Oriahnn 28 Day Kit
- Full name
- Oriahnn 28 Day Kit
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:10
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Oriahnn | ELAGOLIX AND ESTRADIOL AND NORETHISTERONE | AbbVie Inc. | 99f6eee7-7e52-6999-7eb8-488d06dd1710 | 2025-12-19 | Boxed warning, Warnings, Adverse reactions | 2371768 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 99f6eee7-7e52-6999-7eb8-488d06dd1710 | Oriahnn 28 Day Kit | PSN | 41 | These highlights do not include all the information needed to use ORIAHNN safely and effectively. See full prescribing information for ORIAHNN. ORIAHNN ® (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), co-packaged for oral use Initial U.S. Approval: 2020 | 20251219 |
| 99f6eee7-7e52-6999-7eb8-488d06dd1710 | Oriahnn 28 Day Kit | SY | 41 | These highlights do not include all the information needed to use ORIAHNN safely and effectively. See full prescribing information for ORIAHNN. ORIAHNN ® (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), co-packaged for oral use Initial U.S. Approval: 2020 | 20251219 |
| 99f6eee7-7e52-6999-7eb8-488d06dd1710 | {28 (elagolix 300 MG / estradiol 1 MG / norethindrone 0.5 MG Oral Capsule) / 28 (elagolix 300 MG Oral Capsule) } Pack [Oriahnn 28 Day Kit] | BPCK | 41 | These highlights do not include all the information needed to use ORIAHNN safely and effectively. See full prescribing information for ORIAHNN. ORIAHNN ® (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), co-packaged for oral use Initial U.S. Approval: 2020 | 20251219 |